Why James Dack is an Investor in Starpharma, page-10

And page 13
Patients treated with DEP® docetaxel have exhibited:


"No neutropenia (docetaxel dose limiting toxicity)

No alopecia (hair loss) reported

No hypersensitivity

No standard steroid pre-treatment required

Encouraging efficacy signals in a significant proportion of patients including:

in pancreatic (SD*>20 wks), oesophageal (SD >18 wks), prostate, lung, H&N and brain tumours

at low doses, in cancers not responsive to docetaxel and in a heavily pre-treated patient cohort"

Well, I think we have a draft of phase 1 DEP DOX